Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer
Authors:
- Jaime CoronelJCJaime Coronel
- Lucely CetinaLCLucely Cetina
- Aurora González-FierroAGAurora González-Fierro
- Alma Chavez-BlancoACAlma Chavez-Blanco
- Lucia Taja-ChayebLTLucia Taja-Chayeb
- 25 August 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 10 (10) , 1433-1444
Abstract
DNA methylation (DNMTi) and histone deacetylase inhibitors (HDACi) are in development for cancer therapy. So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hydralazine-valproate (TRANSKRIP(™)) is being repositioned as an oral DNMT and HDAC inhibitor. Brief discussion on the current status of epigenetic drugs and studies published on the preclinical and clinical development of the hydralazine-valproate combination. Drug repositioning is a strategy for prompt and cost-efficient drug discovery. There is evidence that combining DNMTi with HDACi would be more efficacious than administering each agent on its own. Hydralazine-valproate is safe when used alone or in combination with chemotherapy or chemoradiation. The fact that both drugs are orally administered is another advantage over current epigenetic drugs. This combination is promising but larger studies are needed. Among these, the randomized Phase III trials in advanced and in locally advanced cervical cancer combined with chemotherapy and cisplatin-radiation respectively, would eventually confirm its efficacy. Studies on MDS and CTCL would also eventually prove the efficacy of hydralazine valproate so that in the coming years hydralazine-valproate could have a role in cancer epigenetic therapy.Keywords
This publication has 68 references indexed in Scilit:
- Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriersPhilosophical Transactions of the Royal Society B: Biological Sciences, 2013
- Epigenetic therapy of hematological malignancies: where are we now?Therapeutic Advances in Hematology, 2012
- Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-CarboxylcytosineScience, 2011
- Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidClinical Epigenetics, 2011
- Response to Hydralazine-Valproate in a Patient with Mycosis FungoidesCase Reports in Medicine, 2010
- Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluationBioorganic & Medicinal Chemistry, 2010
- Rosiglitazone prevents the progression of preinvasive lung cancer in a murine modelCarcinogenesis, 2009
- A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancerBritish Journal of Cancer, 2009
- The prince and the pauper. A tale of anticancer targeted agentsMolecular Cancer, 2008
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005